Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS–based metabolomics approach

Kidney International

Volumn 92, Issue 3, 2017, Pages 634-645

  Mishima, Eikan ^a,b   Fukuda, Shinji ^c,d   Mukawa, Chikahisa ^b   Yuri, Akinori ^b   Kanemitsu, Yoshitomi ^b   Matsumoto, Yotaro ^b   Akiyama, Yasutoshi ^a   Fukuda, Noriko N ^c   Tsukamoto, Hiroki ^b   Asaji, Kei ^b   Shima, Hisato ^a   Kikuchi, Koichi ^a   Suzuki, Chitose ^a   Suzuki, Takehiro ^a   Tomioka, Yoshihisa ^b   Soga, Tomoyoshi ^c   Ito, Sadayoshi ^a   Abe, Takaaki ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

amino acids; chronic kidney disease; gut microbiota; metabolome; short chain fatty acids; uremic toxins

Indexed keywords

2 HYDROXYPENTANOATE; 3 HYDROXY 3 METHYLGLUTARIC ACID; 4 CRESYL SULFATE; ACONITIC ACID; ALLANTOIN; AZELAIC ACID; CHOLIC ACID; CITRIC ACID; CREATININE; CYSTEIC ACID; DIMETHYLGLYCINE; FUMARIC ACID; GAMMA GUANIDINOBUTYRATE; GLUTARIC ACID; HIPPURIC ACID; INDICAN; ISETHIONIC ACID; ISOCITRIC ACID; ITACONIC ACID; MALIC ACID; MALONIC ACID; N ACETYL BETA ALANINE; PANTOTHENIC ACID; PHENACETURATE; PHENYL SULFATE; PIPECOLIC ACID; SEBACIC ACID; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREMIC TOXIN; ADENINE; TOXIN; VOLATILE FATTY ACID;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; INTESTINE FLORA; KIDNEY FAILURE; KIDNEY INJURY; METABOLITE; METABOLOME; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY; UREMIA; ACUTE KIDNEY FAILURE; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DISEASE EXACERBATION; DISEASE MODEL; GERMFREE ANIMAL; HUMAN; KIDNEY; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; URINE;

ACUTE KIDNEY INJURY; ADENINE; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELECTROPHORESIS, CAPILLARY; FATTY ACIDS, VOLATILE; GASTROINTESTINAL MICROBIOME; HUMANS; KIDNEY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MICE; RENAL INSUFFICIENCY, CHRONIC; SPECIFIC PATHOGEN-FREE ORGANISMS; TOXINS, BIOLOGICAL; UREMIA;

EID: 85017254521     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.02.011     Document Type: Article

References (46)

1. Vanholder, R., De Smet, R., Glorieux, G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63 (2003), 1934–1943.
2. Vanholder, R., Meert, N., Schepers, E., et al. Review on uraemic solutes II–variability in reported concentrations: causes and consequences. Nephrol Dial Transplant 22 (2007), 3115–3121.
3. Lekawanvijit, S., Kompa, A.R., Wang, B.H., et al. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res 111 (2012), 1470–1483.
4. Vanholder, R., De Smet, R.I., Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 10 (1999), 1815–1823.
5. Nicholson, J.K., Holmes, E., Kinross, J., et al. Host-gut microbiota metabolic interactions. Science 336 (2012), 1262–1267.
6. Vanholder, R., Schepers, E., Pletinck, A., et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 25 (2014), 1897–1907.
7. Curtius, H.C., Mettler, M., Ettlinger, L., Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 126 (1976), 569–580.
8. Wu, I.W., Hsu, K.H., Hsu, H.J., et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study. Nephrol Dial Transplant 27 (2012), 1169–1175.
9. Wang, Z., Klipfell, E., Bennett, B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
10. Koeth, R.A., Wang, Z., Levison, B.S., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19 (2013), 576–585.
11. Tang, W.H., Wang, Z., Levison, B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368 (2013), 1575–1584.
12. Stubbs, J.R., House, J.A., Ocque, A.J., et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 27 (2016), 305–313.
13. Vaziri, N.D., Wong, J., Pahl, M., et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83 (2013), 308–315.
14. Mishima, E., Fukuda, S., Shima, H., et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 26 (2015), 1787–1794.
15. Toyohara, T., Akiyama, Y., Suzuki, T., et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 33 (2010), 944–952.
16. Wikoff, W.R., Anfora, A.T., Liu, J., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 106 (2009), 3698–3703.
17. Soga, T., Ohashi, Y., Ueno, Y., et al. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2 (2003), 488–494.
18. Matsumoto, M., Kibe, R., Ooga, T., et al. Impact of intestinal microbiota on intestinal luminal metabolome. Sci Rep, 2, 2012, 233.
19. Okuda, S., Yamada, T., Hamajima, M., et al. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res 36 (2008), W423–W426.
20. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47 (2006), 241–259.
21. Romagnoli, G., Verhoeven, M.D., Mans, R., et al. An alternative, arginase-independent pathway for arginine metabolism in Kluyveromyces lactis involves guanidinobutyrase as a key enzyme. Mol Microbiol 93 (2014), 369–389.
22. Ussher, J.R., Lopaschuk, G.D., Arduini, A., Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 231 (2013), 456–461.
23. Vaziri, N.D., Yuan, J., Norris, K., Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 37 (2013), 1–6.
24. Andrade-Oliveira, V., Amano, M.T., Correa-Costa, M., et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26 (2015), 1877–1888.
25. Neis, E.P., Dejong, C.H., Rensen, S.S., The role of microbial amino acid metabolism in host metabolism. Nutrients 7 (2015), 2930–2946.
26. Davila, A.M., Blachier, F., Gotteland, M., et al. Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host. Pharmacol Res 68 (2013), 95–107.
27. Sato, E., Mori, T., Mishima, E., et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep, 6, 2016, 36618.
28. Zhu, W., Gregory, J.C., Org, E., et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell 165 (2016), 111–124.
29. Svingen, G.F., Ueland, P.M., Pedersen, E.K., et al. Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 33 (2013), 2041–2048.
30. Jinnai, D., Sawai, A., Mori, A., Gamma-guanidinobutyric acid as a convulsive substance. Nature, 212, 1966, 617.
31. Gerstner, B., Gratopp, A., Marcinkowski, M., et al. Glutaric acid and its metabolites cause apoptosis in immature oligodendrocytes: a novel mechanism of white matter degeneration in glutaryl-CoA dehydrogenase deficiency. Pediatr Res 57 (2005), 771–776.
32. Mutsaers, H.A., Wilmer, M.J., Reijnders, D., et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta 1832 (2013), 142–150.
33. Russel, F.G., Vermeulen, W.G., Effect of substituted benzoylglycines (hippurates) and phenylacetylglycines on p-aminohippurate transport in dog renal membrane vesicles. Pharm Res 11 (1994), 1829–1833.
34. Chen, J.K., Nagai, K., Chen, J., et al. Phosphatidylinositol 3-kinase signaling determines kidney size. J Clin Invest 125 (2015), 2429–2444.
35. Furusawa, Y., Obata, Y., Fukuda, S., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
36. Smith, P.M., Howitt, M.R., Panikov, N., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341 (2013), 569–573.
37. Chung, S.W., Chan, B.T., Trimethylamine oxide, dimethylamine, trimethylamine and formaldehyde levels in main traded fish species in Hong Kong. Food Addit Contam Part B Surveill 2 (2009), 44–51.
38. Tang, W.H., Wang, Z., Kennedy, D.J., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116 (2015), 448–455.
39. Miyazaki, T., Ise, M., Hirata, M., et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl 63 (1997), S211–S214.
40. Nobukuni, T., Joaquin, M., Roccio, M., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 102 (2005), 14238–14243.
41. Vaziri, N.D., Liu, S.M., Lau, W.L., et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One, 9, 2014, e114881.
42. Jang, H.R., Gandolfo, M.T., Ko, G.J., et al. Early exposure to germs modifies kidney damage and inflammation after experimental ischemia-reperfusion injury. Am J Physiol Renal Physiol 297 (2009), F1457–F1465.
43. Emal D, Rampanelli E, Stroo I, et al. Depletion of gut microbiota protects against renal ischemia-reperfusion injury [e-pub ahead of print]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2016030255. Accessed March 23, 2017.
44. Alexander, A.D., Orcutt, R.P., Henry, J.C., et al. Quantitative PCR assays for mouse enteric flora reveal strain-dependent differences in composition that are influenced by the microenvironment. Mamm Genome 17 (2006), 1093–1104.
45. Poesen, R., Viaene, L., Verbeke, K., et al. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol 8 (2013), 1508–1514.
46. Poesen, R., Evenepoel, P., de Loor, H., et al. Metabolism, protein binding, and renal clearance of microbiota–derived p-cresol in patients with CKD. Clin J Am Soc Nephrol 11 (2016), 1136–1144.